Your browser is no longer supported. Please, upgrade your browser.
Settings
RCUS Arcus Biosciences, Inc. daily Stock Chart
RCUS [NYSE]
Arcus Biosciences, Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own1.00% Shs Outstand45.93M Perf Week11.94%
Market Cap426.23M Forward P/E- EPS next Y-2.29 Insider Trans- Shs Float28.40M Perf Month-3.73%
Income-54.30M PEG- EPS next Q-0.40 Inst Own47.70% Short Float4.16% Perf Quarter-19.65%
Sales8.90M P/S47.89 EPS this Y-12.40% Inst Trans-4.86% Short Ratio8.74 Perf Half Y-21.49%
Book/sh5.09 P/B1.82 EPS next Y-37.10% ROA-19.50% Target Price18.20 Perf Year-42.00%
Cash/sh5.27 P/C1.76 EPS next 5Y- ROE-22.70% 52W Range7.40 - 17.18 Perf YTD-13.83%
Dividend- P/FCF- EPS past 5Y- ROI-23.40% 52W High-45.98% Beta-
Dividend %- Quick Ratio12.90 Sales past 5Y- Gross Margin- 52W Low25.41% ATR0.55
Employees108 Current Ratio12.90 Sales Q/Q38.50% Oper. Margin- RSI (14)54.71 Volatility6.75% 6.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-39.40% Profit Margin- Rel Volume0.69 Prev Close9.29
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume135.17K Price9.28
Recom1.40 SMA208.49% SMA50-7.35% SMA200-17.32% Volume93,089 Change-0.11%
May-24-19Resumed Citigroup Buy $25
Oct-09-18Initiated Wedbush Outperform $22
Apr-09-18Initiated Leerink Partners Outperform $21
Apr-09-18Initiated Goldman Neutral $18
Apr-09-18Initiated Citigroup Buy $18
Jun-11-19 04:10PM  Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs Business Wire
Jun-07-19 04:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $172,382 of Shares GuruFocus.com
Jun-05-19 01:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $328,581 of Shares GuruFocus.com
May-29-19 04:30PM  Arcus Biosciences to Present Preliminary Data from the Ongoing Phase 1 Dose-Escalation Trials of AB928 in Combination with Chemotherapy or AB122 at the 2019 ASCO Annual Meeting Business Wire
May-21-19 04:10PM  Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference Business Wire
May-09-19 08:34PM  Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy? Insider Monkey
May-08-19 09:33AM  Infinity (INFI) Earnings and Sales Miss Estimates in Q1 Zacks
09:15AM  Trade Anxieties Return with a Vengeance Zacks
May-02-19 07:40AM  Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates Business Wire
07:35AM  Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer Business Wire
07:30AM  Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122 Business Wire
Apr-29-19 04:41PM  Arcus (RCUS) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-25-19 09:31AM  Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised Zacks
Apr-11-19 12:05PM  What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)? Simply Wall St.
09:28AM  Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue? Zacks
Mar-25-19 04:10PM  Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer Business Wire
Mar-15-19 11:37AM  Infinity Inks Deal With Roche for Phase II Study of IPI-549 Zacks
Mar-05-19 04:10PM  Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates Business Wire
Feb-28-19 08:30AM  Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting Business Wire
Feb-13-19 04:10PM  Arcus Biosciences Announces Participation at Upcoming Investor Conference Business Wire +7.20%
Jan-04-19 04:34PM  Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today Motley Fool -14.11%
08:30AM  Arcus Biosciences Announces Transition of Chief Financial and Operating Officer Business Wire
Jan-02-19 01:15PM  Here are the winners and losers from Bay Area's IPO class of 2018 American City Business Journals
Dec-05-18 10:35AM  This year's Bay Area IPO batch remains up 44% despite market turbulence American City Business Journals
Nov-16-18 08:55AM  Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-09-18 07:30AM  Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting Business Wire
Nov-08-18 04:05PM  Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates Business Wire +5.15%
Nov-01-18 04:05PM  Arcus Biosciences Announces Participation at Three Investor Conferences in November Business Wire +5.27%
Oct-22-18 08:30AM  Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors Business Wire
Oct-10-18 12:25PM  Do You Know Who Else Invests In Arcus Biosciences Inc (NYSE:RCUS)? Simply Wall St.
Oct-08-18 06:40PM  Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress Business Wire -6.94%
Oct-02-18 04:30PM  Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting Business Wire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals
Sep-20-18 04:05PM  Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
Aug-29-18 04:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $280,407 of Shares GuruFocus.com -6.45%
Aug-24-18 08:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $124,937 of Shares GuruFocus.com
Aug-22-18 04:05PM  Arcus Biosciences Announces Participation at Two Investor Conferences in September Business Wire
Aug-21-18 10:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $117,717 of Shares GuruFocus.com
Aug-16-18 07:15PM  Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $358,989 of Shares GuruFocus.com
Aug-06-18 04:05PM  Arcus Biosciences Announces Second Quarter 2018 Financial Results and Recent Corporate Updates Business Wire
Aug-01-18 04:05PM  Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Jul-30-18 08:00AM  Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody Business Wire
Jul-17-18 08:00AM  Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers Business Wire
Jul-12-18 05:00PM  Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories Business Wire
Jun-26-18 08:30AM  Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies PR Newswire
08:30AM  Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies Business Wire
Jun-12-18 07:00AM  Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer Business Wire
Jun-11-18 07:30AM  Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations Business Wire
May-29-18 04:10PM  Arcus Biosciences Announces Participation at Upcoming Investor Conference Business Wire
May-18-18 08:59PM  Does Arcus Biosciences Incs (NYSE:RCUS) -120.96% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
May-09-18 04:10PM  Arcus Biosciences Announces First Quarter 2018 Financial Results and Recent Corporate Updates Business Wire +6.18%
May-03-18 10:17AM  Fresh $668 million biotech venture fund aims to quench hunger for data American City Business Journals
Apr-17-18 09:00AM  Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting Business Wire
Apr-09-18 05:53PM  In fresh IPO's 77 percent fall, another warning sign for biotech investors American City Business Journals
Apr-06-18 11:19AM  Peninsula anti-aging drug company files for $85M IPO American City Business Journals
Mar-19-18 05:27PM  Arcus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-15-18 04:10PM  Arcus Biosciences Announces Five Abstracts Accepted for Presentation at AACR 2018 Annual Meeting Business Wire
11:00AM  Cancer-fighting East Bay company upsizes IPO, raises $120 million American City Business Journals
Mar-14-18 05:53PM  Arcus Biosciences Announces Pricing of Initial Public Offering Business Wire
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.